Simple Search Results

Query String: EPHB4 KO

CHEMBL1159714 Ko 707 BDBM50421719
3-((3S,6S)-6-Isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indol-3-yl)-propionic acid tert-butyl ester BDBM50305083 3-((3S,6S,12aS)-6-Isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indol-3-yl)-propionic acid tert-butyl ester Ko143 Ko-143 US9695174, Ko143 CHEMBL488910

Mitchell, SA; Danca, MD; Blomgren, PA; Darrow, JW; Currie, KS; Kropf, JE; Lee, SH; Gallion, SL; Xiong, JM; Pippin, DA; DeSimone, RW; Brittelli, DR; Eustice, DC; Bourret, A; Hill-Drzewi, M; Maciejewski, PM; Elkin, LL Imidazo[1,2-a]pyrazine diaryl ureas: inhibitors of the receptor tyrosine kinase EphB4. Bioorg Med Chem Lett 19: 6991-5 (2009)
Bardelle, C; Barlaam, B; Brooks, N; Coleman, T; Cross, D; Ducray, R; Green, I; Brempt, CL; Olivier, A; Read, J Inhibitors of the tyrosine kinase EphB4. Part 3: identification of non-benzodioxole-based kinase inhibitors. Bioorg Med Chem Lett 20: 6242-5 (2010)
Barlaam, B; Ducray, R; Lambert-van der Brempt, C; Plé, P; Bardelle, C; Brooks, N; Coleman, T; Cross, D; Kettle, JG; Read, J Inhibitors of the tyrosine kinase EphB4. Part 4: Discovery and optimization of a benzylic alcohol series. Bioorg Med Chem Lett 21: 2207-11 (2011)
Li, C; Shan, Y; Sun, Y; Si, R; Liang, L; Pan, X; Wang, B; Zhang, J Discovery of novel anti-angiogenesis agents. Part 7: Multitarget inhibitors of VEGFR-2, TIE-2 and EphB4. Eur J Med Chem 141: 506-518 (2017)
Bardelle, C; Coleman, T; Cross, D; Davenport, S; Kettle, JG; Ko, EJ; Leach, AG; Mortlock, A; Read, J; Roberts, NJ; Robins, P; Williams, EJ Inhibitors of the tyrosine kinase EphB4. Part 2: structure-based discovery and optimisation of 3,5-bis substituted anilinopyrimidines. Bioorg Med Chem Lett 18: 5717-21 (2009)
Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486.
Bardelle, C; Cross, D; Davenport, S; Kettle, JG; Ko, EJ; Leach, AG; Mortlock, A; Read, J; Roberts, NJ; Robins, P; Williams, EJ Inhibitors of the tyrosine kinase EphB4. Part 1: Structure-based design and optimization of a series of 2,4-bis-anilinopyrimidines. Bioorg Med Chem Lett 18: 2776-80 (2008)
Lafleur, K; Dong, J; Huang, D; Caflisch, A; Nevado, C Optimization of inhibitors of the tyrosine kinase EphB4. 2. Cellular potency improvement and binding mode validation by X-ray crystallography. J Med Chem 56: 84-96 (2013)
Lafleur, K; Huang, D; Zhou, T; Caflisch, A; Nevado, C Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem 52: 6433-46 (2009)
Pan, X; Liang, L; Si, R; Wang, J; Zhang, Q; Zhou, H; Zhang, L; Zhang, J Discovery of novel anti-angiogenesis agents. Part 10: Multi-target inhibitors of VEGFR-2, Tie-2 and EphB4 incorporated with 1,2,3-triazol. Eur J Med Chem 163: 1-9 (2019)
PubChem, PC Dose-response biochemical assay for antagonists of the interaction between the Eph receptor B4 (EphB4) and its ligand ephrin-B2 via TNYL-RAW peptide PubChem Bioassay (2007)